Repligen (RGEN) Beats Q4 Earnings Estimates

Group 1 - Repligen reported quarterly earnings of $0.44 per share, exceeding the Zacks Consensus Estimate of $0.41 per share, and up from $0.33 per share a year ago, representing an earnings surprise of 7.32% [1] - The company posted revenues of $167.55 million for the quarter ended December 2024, slightly missing the Zacks Consensus Estimate by 0.10%, compared to $155.74 million in the same quarter last year [2] - Over the last four quarters, Repligen has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Group 2 - The stock's immediate price movement will depend on management's commentary during the earnings call, with Repligen shares gaining about 4.7% year-to-date, compared to the S&P 500's gain of 4.5% [3] - The current consensus EPS estimate for the upcoming quarter is $0.37 on revenues of $163.53 million, and for the current fiscal year, it is $1.71 on revenues of $695.77 million [7] - The Medical - Biomedical and Genetics industry, to which Repligen belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook [8]